Tcr2 Therapeutics Inc (NASDAQ:TCRR) major shareholder Morana Jovan-Embiricos sold 64,104 shares of the firm’s stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $17.11, for a total transaction of $1,096,819.44. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

NASDAQ TCRR traded down $0.30 during trading on Friday, reaching $19.23. The company’s stock had a trading volume of 63,922 shares, compared to its average volume of 81,016. The business has a 50-day moving average price of $15.58 and a 200-day moving average price of $15.98. Tcr2 Therapeutics Inc has a 1-year low of $10.04 and a 1-year high of $25.47.

Tcr2 Therapeutics (NASDAQ:TCRR) last posted its earnings results on Thursday, August 8th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.57) by $0.11. As a group, equities analysts anticipate that Tcr2 Therapeutics Inc will post -5.66 EPS for the current year.

Several analysts recently commented on TCRR shares. ValuEngine upgraded shares of Tcr2 Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Roth Capital started coverage on shares of Tcr2 Therapeutics in a report on Friday, May 31st. They set a “neutral” rating and a $16.00 price target for the company. Finally, Zacks Investment Research upgraded shares of Tcr2 Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 price target for the company in a report on Friday, August 30th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $26.33.

Hedge funds and other institutional investors have recently bought and sold shares of the business. MPM Asset Management LLC acquired a new stake in Tcr2 Therapeutics in the first quarter valued at approximately $70,607,000. Redmile Group LLC acquired a new stake in Tcr2 Therapeutics in the first quarter valued at approximately $28,686,000. Dean Capital Investments Management LLC acquired a new stake in Tcr2 Therapeutics in the first quarter valued at approximately $694,000. Vanguard Group Inc. acquired a new stake in Tcr2 Therapeutics in the second quarter valued at approximately $1,070,000. Finally, BlackRock Inc. acquired a new stake in Tcr2 Therapeutics in the second quarter valued at approximately $1,511,000. Hedge funds and other institutional investors own 33.45% of the company’s stock.

About Tcr2 Therapeutics

TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies.

Read More: What is a Buy-Side Analyst?

Receive News & Ratings for Tcr2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tcr2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.